| Drug Name |
Suvorexant |
| Drug ID |
BADD_D02103 |
| Description |
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. |
| Indications and Usage |
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CM19 |
| DrugBank ID |
DB09034
|
| KEGG ID |
D10082
|
| MeSH ID |
C551624
|
| PubChem ID |
24965990
|
| TTD Drug ID |
D00OVU
|
| NDC Product Code |
0006-0325; 0006-0001; 70966-0034; 0006-0003; 50473-0029; 0006-0002; 0006-0033; 0006-0004; 0006-0335; 0006-0005 |
| UNII |
081L192FO9
|
| Synonyms |
suvorexant | (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone | methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)- | MK 4305 | MK4305 | MK-4305 | Belsomra |
